Counting the cost of off-label drug use in the EU
This article was originally published in SRA
Should cost be a factor when considering whether to use a drug off-label?
You may also be interested in...
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
Mutual recognition of approvals and simplified rules on labeling could help to make COVID-19 vaccines more accessible to populations around the world.
The UK BioIndustry Association says the updated guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.